Format

Send to:

Choose Destination
See comment in PubMed Commons below
Alzheimers Dement. 2012 Jul;8(4):337-42. doi: 10.1016/j.jalz.2012.04.007.

Worldwide Alzheimer's disease neuroimaging initiative.

Author information

  • 1Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Maria.Carrillo@alz.org

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2003 to speed drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the first phase of ADNI (ADNI 1) set a new standard for data sharing without embargo. In addition, it has been extended to 2017 by additional funding (North American-ADNI Grand Opportunities and ADNI 2) as well as multiple projects around the world, collectively known as Worldwide ADNI (WW-ADNI). The goal of WW-ADNI is to harmonize projects and results across different geographical sites and to encourage and harmonize data management and availability to investigators around the world. WW-ADNI projects are currently underway in North America, Europe, Japan, Australia, Korea, Taiwan, and Argentina, with a nascent program in China and a possible future program in Brazil.

Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

PMID:
22748939
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk